The probe, led by the DEA’s Diversion Control Division, is looking into Done’s prescribing practices for stimulants such as Adderall.
Done said in a statement to the Journal that it hasn’t received any notifications from the DEA or any other federal agency regarding an investigation, request for records or preservation of documents and that the company is committed to providing high-quality psychiatric care while complying with all applicable laws and regulations.
The alleged investigation comes after a 2021 internal company report, written by Done’s former chief medical officer, said that “multiple Done providers have specifically expressed a perception of pressure to diagnose ADHD and prescribe stimulants.”
Done has said that report was irrelevant to its business and that its clinicians use their judgment and follow proper procedures.
The company is among the lastest telehealth companies to come under scrutiny by the Justice Department.
Telehealth startup Cerebral was subpoenaed by federal prosecutors on May 4 after allegations of overprescribing controlled substances.
Cerebral has since discontinued prescriptions for controlled substances.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
